Sun Pharma recalls 16K bottles of antidepressant tablets in US

By: | Published: July 27, 2016 9:56 PM

The class III recall is due to 'failed dissolution specifications', the report on the website of United States Food and Drug Administration (USFDA) said.

The buPROPion hydrochloride extended release tablets were manufactured at the company's Halol facility. (Reuters) The buPROPion hydrochloride extended release tablets were manufactured at the company’s Halol facility. (Reuters)

Drug major Sun Pharmaceutical Industries is recalling over 16,000 bottles of an anti-depressant tablets from the US market due to failed dissolution specifications.

The buPROPion hydrochloride extended release tablets were manufactured at the company’s Halol facility.

Sun Pharmaceutical Industries Inc, the company’s US subsidiary, is recalling 16,085 bottles of buPROPion hydrochloride extended release tablets in the strength of 150 mg in a ongoing voluntary nationwide recall, the latest Enforcement Report of the USFDA said.

The class III recall is due to ‘failed dissolution specifications’, the report on the website of United States Food and Drug Administration (USFDA) said.

As per the USFDA a class III recall is initiated in “a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition